RaySearch Laboratories AB has received an order for its RayStation® treatment planning system from The Radiation Oncology Institute in New South Wales, Australia.
The Radiation Oncology Institute (ROI) runs two radiation therapy centers in Wahroonga and Gosford in New South Wales. Radiation Oncology Institute - Wahroonga is located in the Sydney region. Situated in the grounds of the Sydney Adventist Hospital, Radiation Oncology Institute - Wahroonga is a private medical specialist practice originally founded in 1936. Since then the practice has grown and in 1976 commenced in its current site as the second practice in New South Wales to be located outside of a Public Hospital. The Gosford centre was opened for its first patients in August 1995 to service the patients of the Central Coast who had been travelling to Sydney for treatment. Today Radiation Oncology Institute - Gosford remains the only radiation therapy facility on the Central Coast and treats more than 500 new patients every year.
ROI will use RayStation® as its treatment planning system for conventional 3D-CRT treatments, as well as more advanced treatments, such as IMRT and VMAT. The order also includes advanced tools enabling a more efficient treatment planning process, such as Multi-Criteria Optimization. This highly intuitive tool lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming treatment planning optimization process. In addition the order also includes fully integrated tools for deformable registration, dose accumulation and adaptive radiotherapy. RayStation® will then allow the center to use advanced techniques to assess the need for re-planning based on accumulated delivered dose using special adaptive techniques to adjust for anatomical changes occurring during the course of treatment. If re-planning is needed, RayStation® will allow the clinicians seamlessly re-optimize the plan based on dose that has already been delivered.
“ROI selected RayStation® because of its class leading features that will allow us to provide the most advanced treatment planning techniques including the ability to provide patient based optimal solutions utilizing RayStation’s unique adaptive treatment planning and dose tracking features combined with Multi-Criteria Optimization. We are excited to be the first in Australia to use Raystation® and look forward to a long and successful association”, says Susan Mainey, CEO of Radiation Oncology Institute.
Johan Löf, CEO of RaySearch Laboratories adds: “We see a lot of interest for RayStation® in the Australasian region so we are very happy to announce this first order in Australia. The Radiation Oncology Institute runs two great treatment centers and we are of course delighted that they have selected RayStation® as their treatment planning system for the future.”
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for both photon and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA Dosimetry, Varian, Accuray and Siemens. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30